Source: Eur Respir Rev 2017; 26: 160055
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Olivier Sitbon, Anton Vonk Noordegraaf. Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience. Eur Respir Rev 2017; 26: 160055

Member's Comments

No comment yet.

Related content which might interest you: Selexipag real-world experience in patients over 75 yrs with pulmonary arterial hypertension (PAH) Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 A decade of achievement in pulmonary arterial hypertension Source: Annual Congress 2012 - The European Respiratory Review: what's hot in pulmonary medicine Year: 2012 Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003 Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006 Bosentan treatment for pulmonary arterial hypertension related to congenital heart disease: real-world clinical experience in Spain Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Modern age pathology of pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012 Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary circulation Year: 2007 COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey Source: ERJ Open Res, 6 (4) 00520-2020; 10.1183/23120541.00520-2020 Year: 2020 The French registry of pulmonary arterial hypertension in children: characteristics at diagnosis Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Pulmonary arterial hypertension: a comparison between children and adults Source: Eur Respir J 2011; 37: 665-677 Year: 2011 Current medical treatment of pulmonary arterial hypertension Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2017 Current medical treatment of pulmonary arterial hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 Current medical treatment of pulmonary arterial hypertension Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014 Current medical treatment of pulmonary arterial hypertension Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease Year: 2018 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005